Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).

NCT01717807 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT01717807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01717807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
Lead sponsor
Hadassah Medical Organization
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2013
Completion date
Not reported
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, pancreatic cancer